{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:28:37Z","timestamp":1769218117306,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jtauto.2019.100016","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T11:48:38Z","timestamp":1567770518000},"page":"100016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Subcutaneous abatacept in rheumatoid arthritis: A real-life experience"],"prefix":"10.1016","volume":"2","author":[{"given":"Juan Camilo","family":"Sarmiento-Monroy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Parada-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Rodr\u00edguez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Molano-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rojas-Villarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n Dar\u00edo","family":"Mantilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2019.100016_bib1","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"Suppl 1","key":"10.1016\/j.jtauto.2019.100016_bib2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s10067-015-3012-0","article-title":"Burden of illness of rheumatoid arthritis in Latin America: a regional perspective","volume":"34","author":"Ram\u00edrez","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jtauto.2019.100016_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2019.100016_bib5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1517\/14712598.2015.1065248","article-title":"Subcutaneous abatacept in rheumatoid arthritis: current update","volume":"15","author":"Keystone","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jtauto.2019.100016_bib6","doi-asserted-by":"crossref","first-page":"26762","DOI":"10.1074\/jbc.271.43.26762","article-title":"Covalent dimerization of CD28\/CTLA-4 and oligomerization of CD80\/CD86 regulate T cell costimulatory interactions","volume":"271","author":"Greene","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jtauto.2019.100016_bib7","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2019.100016_bib8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","article-title":"Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study","volume":"65","author":"Nash","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jtauto.2019.100016_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/annrheumdis-2011-200344","article-title":"Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)","volume":"71","author":"Kaine","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2019.100016_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/annrheumdis-2011-200355","article-title":"Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jtauto.2019.100016_bib11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/annrheumdis-2016-eular.5165","article-title":"AB0354 Subcutaneous abatacept in patients with rheumatoid arthritis: a real-life experience","volume":"75","author":"Sarmiento-Monroy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtauto.2019.100016_bib12","doi-asserted-by":"crossref","unstructured":"Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health n.d.;10:326\u2013335. doi:10.1111\/j.1524-4733.2007.00186.x.","DOI":"10.1111\/j.1524-4733.2007.00186.x"},{"key":"10.1016\/j.jtauto.2019.100016_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2474-15-14","article-title":"Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study","volume":"15","author":"N\u00fc\u00dflein","year":"2014","journal-title":"BMC Muscoskelet. Disord."},{"key":"10.1016\/j.jtauto.2019.100016_bib14","first-page":"1","article-title":"Predictive factors for structural remission using abatacept: results from the ABROAD study","author":"Murakami","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib15","first-page":"1","article-title":"Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data","author":"Takabayashi","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3899\/jrheum.141288","article-title":"Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks","volume":"42","author":"Takahashi","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12891-015-0636-9","article-title":"Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study","volume":"16","author":"N\u00fc\u00dflein","year":"2015","journal-title":"BMC Muscoskelet. Disord."},{"key":"10.1016\/j.jtauto.2019.100016_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-016-0956-7","article-title":"Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry","volume":"18","author":"Truchetet","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2019.100016_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000040","article-title":"The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries","volume":"1","author":"Finckh","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.jtauto.2019.100016_bib20","first-page":"30","article-title":"Seguridad de abatacept en pacientes con artritis reumatoidea","volume":"23","author":"Dal Pra","year":"2012","journal-title":"Rev. Argent. Reumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib21","first-page":"200","article-title":"Costo efectividad de Abatacept en comparaci\u00f3n con otras terapias biol\u00f3gicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han fallado al tratamiento con metotrexato en EsSalud para el a\u00f1o 2010","volume":"28","author":"Becerra Rojas","year":"2011","journal-title":"Acta Med."},{"key":"10.1016\/j.jtauto.2019.100016_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/annrheumdis-2012-202779","article-title":"EULAR definition of erosive disease in light of the 2010 ACR\/EULAR rheumatoid arthritis classification criteria","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2019.100016_bib23","author":"Pinheiro"},{"key":"10.1016\/j.jtauto.2019.100016_bib24","series-title":"A\u00a0Language and Environment for Statistical Computing","first-page":"201","year":"2017"},{"key":"10.1016\/j.jtauto.2019.100016_bib25","first-page":"1","article-title":"Introducing polyautoimmunity: secondary autoimmune diseases No longer exist","volume":"254319","author":"Rojas-Villarraga","year":"2012","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.jtauto.2019.100016_bib26","series-title":"4th Int. Congr. Controv. Rheumatol. Autoimmun. CORA 2017","article-title":"Correlation between routine assessment of patient index data 3 (RAPID3) and disease activity score 28 (DAS28) in patients with rheumatoid arthritis treated with subcutaneous abatacept","author":"Sarmiento-Monroy","year":"2017"},{"key":"10.1016\/j.jtauto.2019.100016_bib27","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3899\/jrheum.080182","article-title":"RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories","volume":"35","author":"Pincus","year":"2008","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jtauto.2019.100016_bib29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jtauto.2019.100016_bib30","doi-asserted-by":"crossref","unstructured":"Mola EM, Balsa A, Mart\u00ednez Taboada V, Marenco JL, Navarro Sarabia F, G\u00f3mez-Reino J, et\u00a0al. Practice guidelines for the use of subcutaneous abatacept. Reumatol Clin n.d.;10:218\u2013226. doi:10.1016\/j.reuma.2013.11.006.","DOI":"10.1016\/j.reumae.2013.11.009"},{"key":"10.1016\/j.jtauto.2019.100016_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","article-title":"Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study","volume":"36","author":"Desplats","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib32","series-title":"Abatacepte para o tratamento da Artrite Reumatoide Moderada a Grave. Brazil","author":"Conitec","year":"2016"},{"key":"10.1016\/j.jtauto.2019.100016_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/14397595.2015.1012786","article-title":"Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders","volume":"25","author":"Amano","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-016-0985-2","article-title":"Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)","volume":"18","author":"Mueller","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2019.100016_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3899\/jrheum.141042","article-title":"Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety","volume":"42","author":"Reggia","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib36","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3899\/jrheum.150230","article-title":"Switching from intravenous to subcutaneous formulation of abatacept: different results in a series of 21 patients","volume":"42","author":"Monti","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib37","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","article-title":"Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis","volume":"36","author":"D\u2019Agostino","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J.\u00a0Multidiscip. Healthc."},{"key":"10.1016\/j.jtauto.2019.100016_bib39","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","article-title":"Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment","volume":"66","author":"Alten","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2019.100016_bib40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.170344","article-title":"Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial","volume":"45","author":"Genovese","year":"2018","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib41","series-title":"10th Int. Congr. Autoimmun.","article-title":"Factors associated with response to abatacept in rheumatoid arthritis: a systematic literature review","author":"Sarmiento-Monroy","year":"2016"},{"key":"10.1016\/j.jtauto.2019.100016_bib42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3899\/jrheum.091176","article-title":"Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response","volume":"37","author":"Scarsi","year":"2010","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib43","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3899\/jrheum.110386","article-title":"Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis","volume":"38","author":"Scarsi","year":"2011","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib44","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u201cOrencia and Rheumatoid Arthritis\u201d registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2019.100016_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2019.100016_bib46","first-page":"494","article-title":"Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data","volume":"29","author":"Yazici","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib47","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00296-015-3283-4","article-title":"Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use","volume":"35","author":"Takahashi","year":"2015","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jtauto.2019.100016_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtauto.2019.100016_bib49","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","article-title":"Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-european registry analysis","volume":"68","author":"Gottenberg","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2019.100016_bib50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.170007","article-title":"Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US national observational study","volume":"45","author":"Harrold","year":"2018","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib51","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3899\/jrheum.160051","article-title":"Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study","volume":"43","author":"Sekiguchi","year":"2016","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2019.100016_bib52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.rdc.2017.04.008","article-title":"Precision medicine in rheumatoid arthritis","volume":"43","author":"Bluett","year":"2017","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jtauto.2019.100016_bib53","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J.\u00a0Korean Med. Sci."}],"updated-by":[{"DOI":"10.1016\/j.jtauto.2020.100041","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000}}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909019300164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909019300164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:32:54Z","timestamp":1762903974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909019300164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"alternative-id":["S2589909019300164"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2019.100016","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous abatacept in rheumatoid arthritis: A real-life experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2019.100016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100016"}}